Why the study?
Does captopril alter pituitary-adrenocortical activity in patients with drug-resistant essential hypertension?
Does captopril alter pituitary-adrenocortical activity in patients with drug-resistant essential hypertension?
Captopril treatment does not appear to influence glucocorticoid activity via decreased plasma angiotensin II concentrations in patients with essential hypertension.
Answers are grounded in this paper and cite their sources.
Captopril did not alter ACTH or cortisol in this case; leaves open any effect on pituitary-adrenocortical activity in resistant hypertension.
To study effects on pituitary-adrenocortical activity of a sustained block of angiotensin II formation, six 'drug-resistant' patients with essential hypertension were studied before and during treatment with an inhibitor of the angiotensin-converting enzyme (Captopril, SQ 14,225). The drug was given in increasing doses (100-400 mg/day) for 2 weeks whilst patients received a moderately restricted sodium intake (60-80 mmol/day). Immunoreactive ACTH, cortisol, aldosterone, plasma renin activity (PRA) and the activity of the angiotensin-converting enzyme (ACE) were measured in blood samples drawn at 0800-0900 h. Urinary excretion of cortisol and aldosterone were measured in 24-h urine collections. Further information on pituitary-adreno-cortical function was obtained by measuring serial plasma corticosteroid levels after submaximal stimulation with a synthetic ACTH preparation. ACTH and cortisol did not change an observation which does not support the hypothesis that glucocorticoid activity is influenced by a decrease in plasma angiotensin II concentrations.
No takes yet. Share an insight, caveat, or question.
Angeli et al. (1981) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: